Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Ultragenyx Pharmaceutical Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Ultragenyx Pharmaceutical kazanç ve gelirin sırasıyla yıllık 50.7% ve 30.9% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 53% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -55.3% olacağı tahmin edilmektedir.

Anahtar bilgiler

50.7%

Kazanç büyüme oranı

53.0%

EPS büyüme oranı

Biotechs kazanç büyümesi	28.8%
Gelir büyüme oranı	30.9%
Gelecekteki özkaynak getirisi	-55.3%
Analist kapsamı	Good
Son güncelleme	26 Sep 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt

Sep 04

Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective

Aug 22

There's Reason For Concern Over Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Massive 26% Price Jump

Aug 03

Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being

Jun 12

There's No Escaping Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Muted Revenues Despite A 28% Share Price Rise

Dec 28

Is There An Opportunity With Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) 47% Undervaluation?

Sep 12

An Intrinsic Calculation For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Suggests It's 50% Undervalued

May 24

Improved Revenues Required Before Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Find Their Feet

Apr 17

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 33% Below Their Intrinsic Value Estimate

Feb 18

Ultragenyx upgraded to buy at Guggenheim as stock trading at discount to biotech peers

Oct 13

Ultragenyx grants stock options, restricted stock units

Oct 05

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:RARE - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	848	-337	-235	-321	16
12/31/2025	625	-495	-293	-334	20
12/31/2024	537	-553	-413	-369	19
6/30/2024	481	-585	-492	-469	N/A
3/31/2024	443	-613	-544	-509	N/A
12/31/2023	434	-607	-522	-475	N/A
9/30/2023	410	-635	-553	-481	N/A
6/30/2023	403	-721	-553	-459	N/A
3/31/2023	384	-719	-529	-420	N/A
12/31/2022	363	-707	-527	-380	N/A
9/30/2022	343	-678	-480	-344	N/A
6/30/2022	334	-506	-438	-309	N/A
3/31/2022	332	-470	-416	-297	N/A
12/31/2021	351	-454	-412	-339	N/A
9/30/2021	360	-356	-426	-347	N/A
6/30/2021	359	-351	-411	-349	N/A
3/31/2021	334	-204	-243	-196	N/A
12/31/2020	271	-187	-176	-132	N/A
9/30/2020	215	-256	-175	-142	N/A
6/30/2020	159	-301	-203	-168	N/A
3/31/2020	122	-425	-381	-345	N/A
12/31/2019	104	-403	-370	-345	N/A
9/30/2019	84	-397	-344	-329	N/A
6/30/2019	70	-371	-320	-310	N/A
3/31/2019	59	-325	-304	-297	N/A
12/31/2018	51	-198	-295	-291	N/A
9/30/2018	38	-192	-320	-317	N/A
6/30/2018	26	-183	-313	-309	N/A
3/31/2018	13	-204	N/A	-282	N/A
12/31/2017	3	-302	N/A	-254	N/A
9/30/2017	0	-292	N/A	-220	N/A
6/30/2017	0	-277	N/A	-186	N/A
3/31/2017	0	-261	N/A	-177	N/A
12/31/2016	0	-246	N/A	-161	N/A
9/30/2016	0	-230	N/A	-154	N/A
6/30/2016	0	-204	N/A	-156	N/A
3/31/2016	N/A	-177	N/A	-133	N/A
12/31/2015	N/A	-146	N/A	-106	N/A
9/30/2015	N/A	-107	N/A	-78	N/A
6/30/2015	N/A	-84	N/A	-58	N/A
3/31/2015	N/A	-68	N/A	-52	N/A
12/31/2014	N/A	-65	N/A	-45	N/A
9/30/2014	N/A	-67	N/A	-42	N/A
6/30/2014	N/A	-63	N/A	-38	N/A
3/31/2014	N/A	-61	N/A	-36	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: RARE önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: RARE önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: RARE önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: RARE şirketinin gelirinin (yıllık 30.9% ) US pazarından (yıllık 8.7% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: RARE şirketinin gelirinin (yıllık 30.9% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: RARE 3 yıl içinde kârsız olması bekleniyor.

Ultragenyx Pharmaceutical Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Ultragenyx Pharmaceutical Inc. Increases Revenue Guidance for the Year 2024

Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2024

Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Full Year 2024

Ultragenyx Pharmaceutical Inc. Provides Revenue Guidance for 2024

Ultragenyx Pharmaceutical Inc. Provides Earnings Guidance for the Full Year 2023

Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Full Year 2023

Recent updates

Ultragenyx Pharmaceutical Inc. Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

Founder recently sold US$1.1m worth of stock

Founder notifies of intention to sell stock

We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt

Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective

Founder recently sold US$1.0m worth of stock

There's Reason For Concern Over Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Massive 26% Price Jump

Ultragenyx Pharmaceutical Inc. Increases Revenue Guidance for the Year 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Ultragenyx Pharmaceutical Inc. Announces Successful End-Of-Phase 2 Meeting with Fda for Gtx-102 Angelman Syndrome Program

Insufficient new directors

Ultragenyx Pharmaceutical Inc. has completed a Follow-on Equity Offering in the amount of $350.000022 million.

Insider recently sold US$441k worth of stock

Ultragenyx Pharmaceutical Inc. Announces Successful Meeting with the FDA

Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc Announce Positive 14-Month Results from the Phase 2 Portion of the Ongoing Phase 2/3 Orbit Study

Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being

Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching

Ultragenyx Pharmaceutical Inc. Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2024

Ultragenyx Pharmaceutical Inc. Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

Ultragenyx Pharmaceutical Inc., Annual General Meeting, Jun 18, 2024

Ultragenyx Pharmaceutical Inc. Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102

Independent Director recently sold US$620k worth of stock

Independent Director notifies of intention to sell stock

Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success Yet

Ultragenyx Pharmaceutical Inc. has filed a Follow-on Equity Offering in the amount of $350 million.

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Full Year 2024

Founder notifies of intention to sell stock

Ultragenyx Pharmaceutical Inc. Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)

Will Ultragenyx Pharmaceutical (NASDAQ:RARE) Spend Its Cash Wisely?

Ultragenyx Pharmaceutical Inc. Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

New major risk - Financial position

Mereo Biopharma Group plc Provides Update on Pipeline Progress and Corporate Developments

Ultragenyx Pharmaceutical Inc. Provides Revenue Guidance for 2024

Founder notifies of intention to sell stock

There's No Escaping Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Muted Revenues Despite A 28% Share Price Rise

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx Pharmaceutical Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Founder notifies of intention to sell stock

Ultragenyx Pharmaceutical Inc. Announces Program and Pipeline Updates At Analyst Day Including Interim Data from Ongoing Studies in Osteogenesis Imperfecta (Oi), Angelman Syndrome (As) and Wilson Disease

New major risk - Financial position

Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)

Ultragenyx Pharmaceutical Inc. Launches Evkeeza (Enacumab for Injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)

Is There An Opportunity With Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) 47% Undervaluation?

New minor risk - Financial position

Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ultragenyx Pharmaceutical Inc. Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

Ultragenyx Pharmaceutical Inc. Announces Appointment of Howard Horn as Chief Financial Officer, Effective October 16, 2023

Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) dropped from Russell Small Cap Comp Value Index

Ultragenyx Pharmaceutical Inc. Announces Data from the Dose- Selection Phase 2/3 Orbit Study

An Intrinsic Calculation For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Suggests It's 50% Undervalued

Insider notifies of intention to sell stock

Ultragenyx Pharmaceutical Inc. Announces U.S. Food and Drug Administration Reviews and Agrees to Protocol Amendment to the Phase 1/2 Study of GTX-102

Ultragenyx Pharmaceutical Inc. Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy 2023 Annual Meeting

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Ultragenyx Pharmaceutical Inc. Reaffirms Earning Guidance for the Full Year 2023

Improved Revenues Required Before Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Find Their Feet

Chief Medical Officer & Executive VP recently sold US$176k worth of stock

Ultragenyx Pharmaceutical Inc. Reaffirms Full Year Earnings Guidance for the Year 2023

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 33% Below Their Intrinsic Value Estimate

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Founder notifies of intention to sell stock

Ultragenyx Pharmaceutical Inc. Provides Revenue Guidance for the Year 2022 and 2023